- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation stock price live, this page displays NASDAQ DVAX stock exchange data. View the DVAX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Dynavax Technologies Corporation real time stock price chart below.
What Is the Dynavax Technologies Corporation Stock Price Today?
The Dynavax Technologies Corporation stock price today is 15.500.
What Is the Stock Symbol for Dynavax Technologies Corporation?
The stock symbol for Dynavax Technologies Corporation is "DVAX."
What Stock Exchange Does Dynavax Technologies Corporation Trade On?
Dynavax Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is Dynavax Technologies Corporation a Good Stock to Buy?
Determining whether Dynavax Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVAX quote. (ISIN: US2681582019)
What Is the Dynavax Technologies Corporation Stock Price Today?
The Dynavax Technologies Corporation stock price today is 15.500.
What Is the Stock Symbol for Dynavax Technologies Corporation?
The stock symbol for Dynavax Technologies Corporation is "DVAX."
What Stock Exchange Does Dynavax Technologies Corporation Trade On?
Dynavax Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is Dynavax Technologies Corporation a Good Stock to Buy?
Determining whether Dynavax Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVAX quote. (ISIN: US2681582019)
15.500
0.000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.490
15.500
52 wk Range
9.200
15.730
Showing Dynavax historical data. For real-time data please try another search
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.49015.500
52 wk Range
9.20015.730
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
22.000
Upside
+41.94%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Dynavax president Novack sells $1.78m in shares
- Investing.com
- Dynavax president Novack sells $1.78m in shares
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. As of February 9, 2026, Dynavax Technologies Corporation operates as a subsidiary of Sanofi.
Dynavax Technologies Corporation SWOT Analysis
HEPLISAV-B Dominance | Explore Dynavax's market leadership with HEPLISAV-B, capturing 45% of the U.S. hepatitis B vaccine market and driving robust financial performance |
Pipeline Potential | Delve into Dynavax's diverse vaccine pipeline, including candidates for shingles, plague, and Lyme disease, positioning the company for future growth |
Financial Strength | Learn about Dynavax's strong cash position of $625 million, supporting R&D efforts and strategic initiatives while maintaining financial stability |
Market Outlook | Analysts project a $32 price target, with the U.S. adult hepatitis B vaccine market expected to reach $900 million by 2030, promising continued growth |
Dynavax Technologies Corporation Earnings Call Summary for Q3/2025
- Dynavax reported Q3 2025 EPS of $0.21, exceeding forecasts by 61.54%, with revenue reaching $94.9 million, up 18% year-over-year, driving a 2.49% stock increase in aftermarket trading.
- Flagship product Heplisav-B captured 46% market share, with significant retail sector gains, contributing to net product revenue of $90 million, a 13% increase from Q3 2024.
- GAAP net income rose to $27 million from $18 million in Q3 2024, while non-GAAP adjusted EBITDA reached $36 million, up from $25 million last year.
- Management raised full-year 2025 adjusted EBITDA guidance to at least $80 million and projected Heplisav-B revenue between $315-325 million by year-end.
- CEO Ryan Spencer highlighted upcoming pipeline milestones in H2 2026, including potential expansions in COVID-19 and shingles vaccine programs with opportunities for strategic partnerships.
Last Updated: 2025/11/06, 00:24
Read Full TranscriptCompare DVAX to Peers and Sector
Metrics to compare | DVAX | Peers Peers - average of corresponding metrics from companies closely matching DVAX: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDVAXPeersSector |
|---|---|---|---|---|
P/E Ratio | −40.6x | 0.0x | −0.5x | |
PEG Ratio | 0.12 | 0.00 | 0.00 | |
Price/Book | 3.3x | 0.0x | 2.6x | |
Price / LTM Sales | 5.3x | 0.0x | 3.3x | |
Upside (Analyst Target) | 61.3% | 0.0% | 47.0% | |
Fair Value Upside | Unlock | 0.0% | 6.1% | Unlock |
Analyst Ratings
1 Buy
1 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 22.000
(+41.94% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
0.21 / 0.13
Revenue / Forecast
94.90M / 94.41M
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.